Skip to main content
SpringerLink
Log in

Guillain-Barré-Syndrom (GBS) und chronische inflammatorische demyelinisierende Polyneuritis (CIDP)

  • Chapter
Immunglobuline in der klinischen Neurologie

  • 90 Accesses

Zusammenfassung

Das Guillain-Barré-Syndrom (GBS) ist diejenige neuroimmunologische Erkrankung, bei der auch nach Kriterien der evidenzbasierten Medizin die gesicherte Indikation für den Einsatz von Immunglobulinen gegeben ist. In mehreren randomisierten und kontrollierten Studien wurde gezeigt, dass IVIg ebenso wie die Plasmaseparation in der Lage sind, den Gesamtverlauf und die Zeit einer etwaigen Respiratorpflicht signifikant zu verkürzen.

Bei der chronischen Variante des GBS, der chronischen inflammatorischen demyelinisierenden Polyneuritis (CIDP) wurden IVIg in mehreren unkontrollierten Studien eingesetzt mit Responderraten zwischen 60 und 80%. In wenigen randomisierten placebokontrollierten Studien waren die Ergebnisse nicht einheitlich. Ein Effekt von IVIg bei der CIDP ist insbesondere dann zu erwarten, wenn die Krankheitsdauer kürzer als ein Jahr ist, eine progrediente Symptomatik bis zum Beginn der Behandlung besteht, sowohl Arme als auch Beine von Paresen betroffen sind, eine Areflexie vorliegt und die motorische Nervenleitgeschwindigkeit des N. medianus verlangsamt ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Barnett MH, Pollard JD, Davies L, McLeod JG (1998) Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21:454–460

    Article  PubMed  CAS  Google Scholar 

  2. Berlit P, Rakicky J (1992) The Miller Fisher Syndrome. Clin Neuro-ophthalmology 12:57–63

    CAS  Google Scholar 

  3. Berlit P, Weng Y (1996) Immunglobulinbehandlung der chronisch inflammatorischen demyelinisierenden Polyradikulitis. Nervenheilkunde 15:346–352

    Google Scholar 

  4. Bouchard C, Lacroix C, Planté V, Adams D, Chedru F, Guglielmi JM, Said G (1999) Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52:498–503

    PubMed  CAS  Google Scholar 

  5. Choudhary PP, Hughes RAC (1995) Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QF Med 88:493–502

    CAS  Google Scholar 

  6. Dalakas MC (1999) Intravenous immunoglublin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22:1479–1497

    Article  PubMed  CAS  Google Scholar 

  7. Dutch Guillain-Barré Syndrome Study Group (1994) Treatment of Guillain-Barré syndrome with high-dose immunoglobulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749–752

    Article  Google Scholar 

  8. Dyck PJ, O’Brien PC, Swanson C, Low P, Daube J (1985) Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 35:1173–1176

    PubMed  CAS  Google Scholar 

  9. Dyck PJ, Litchy WJ, Kratz KM, Surez GA, Low PA, Pneda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845

    Article  PubMed  CAS  Google Scholar 

  10. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22:753–761

    Article  Google Scholar 

  11. Good JL, Chehrenama M, Mayer RF, Koski CL (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51:1735–1738

    PubMed  CAS  Google Scholar 

  12. Guillain-Barré Study Group (1985) Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096–1104

    Google Scholar 

  13. Guillain-Barré Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341:586–590

    Google Scholar 

  14. Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV, Swan AV, and the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1998) Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Ann Neurol 44:780–788

    Article  PubMed  CAS  Google Scholar 

  15. Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC (1999) Randomized trial of interferon β-la in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57–61

    PubMed  CAS  Google Scholar 

  16. Hahn AF (1998) Guillain-Barré syndrome. Lancet 352:635–641

    Article  PubMed  CAS  Google Scholar 

  17. Hahn AF (1998) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 51:16–21

    Google Scholar 

  18. Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebocontrolled, cross-over study. Brain 119:1067–1077

    Article  PubMed  Google Scholar 

  19. Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome — Part I. Muscle Nerve 18:137–153

    Article  PubMed  CAS  Google Scholar 

  20. Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome — Part II. Muscle Nerve 18:154–164

    Article  PubMed  CAS  Google Scholar 

  21. Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, McKhanna GM (1997) Patterns of clinical recovery in Guillain-Barré syndrome. Neurology 48:695–700

    PubMed  CAS  Google Scholar 

  22. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, Griffin JW, McKhann GM (1999) Anti-GD la antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 45:168–173

    Article  PubMed  CAS  Google Scholar 

  23. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P (1992) Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 49:612–616

    Article  PubMed  CAS  Google Scholar 

  24. Jacobs BC, Rothbarth PH, van der Meché FGA, Herbrink P, Schmitz PIM, de Klerk MA, van Doom PA (1998) The spectrum of antecedent infections in Guillain-Barré syndrome. Neurology 51:1110–1115

    PubMed  CAS  Google Scholar 

  25. Kanra G, Uzon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H (1997) Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Pediatr Neurol 1:7–12

    Article  CAS  Google Scholar 

  26. Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T (1998) Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti GM1 antibody. Neurology 51:1656–1660

    PubMed  CAS  Google Scholar 

  27. Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, Yuki N (2001) Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG Anti-GMl antibody. Muscle Nerve 24:54–58

    Article  PubMed  CAS  Google Scholar 

  28. Molenaar DSM, van Doom PA, Vermeulen M (1997) Pulsed high dose dexametha-sone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 62:388–390

    Article  PubMed  CAS  Google Scholar 

  29. Nevo V, Pestronk A, Kornberg AJ et al (1996) Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 47:98–102

    PubMed  CAS  Google Scholar 

  30. Otten et al (1995) Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 59:359–361

    Article  Google Scholar 

  31. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet 349:225–230

    Article  Google Scholar 

  32. Qurshi AI, Choudhry MA, Akbar MS, Mohammed Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT (1999) Plasma exchange versus intravenous Immunglobulin treatment in myasthenic crisis. Neurology 52:629–632

    Google Scholar 

  33. Oh SJ, LaGanke C, Claussen GC (2001) Sensory Guillain-Barré syndrome. Neurology 56:82–86

    PubMed  CAS  Google Scholar 

  34. Simmons Z, Wald JJ, Albers JW (1997) Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 20:1569–1575

    Article  PubMed  CAS  Google Scholar 

  35. Sorensen PS (1999) Intravenous immunoglobulin treatment in neurologic disorders. Arch Neurol 56:1025–1032

    Article  PubMed  CAS  Google Scholar 

  36. The French Cooperative Group on Plasma Exchange in Guillain-Barré-Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 41:298–306

    Article  Google Scholar 

  37. Trojaborg W (1998) Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Electroencephalography and clinical Neurophysiology 107:303–316

    Article  PubMed  CAS  Google Scholar 

  38. van der Meché FGA, van Doom PA (1997) The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 20:136–147

    Article  PubMed  Google Scholar 

  39. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrom. N Engl J Med 326:1123–1129

    Article  Google Scholar 

  40. van Doom PA, Brand A, Strenger PFW, Meulstee J, Vermeulen M (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209–212

    Google Scholar 

  41. van Doom PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 48:217–220

    Article  Google Scholar 

  42. van Doom PA (1994) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 57:38–42

    Article  Google Scholar 

  43. Vermeulen M, van Doom PA, Brand A, Stengers PFW, Jennekens FGI, Busch HGM (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39

    Article  PubMed  CAS  Google Scholar 

  44. Visser LH, Schmitz PIM, Meulstee J, van Doorn PA, van der Meché FGA (1999) Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 53:598–604

    PubMed  CAS  Google Scholar 

  45. Visser LH, Van der Meche FG, Meulstee J, van Doorn PA (1998) Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry 64:242–244

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Berlit
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik mit Klinischer Neurophysiologie, Alfried Krupp Krankenhaus, Alfried-Krupp-Straße 21, 45117, Essen, Deutschland

    Peter Berlit

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Berlit, P. (2001). Guillain-Barré-Syndrom (GBS) und chronische inflammatorische demyelinisierende Polyneuritis (CIDP). In: Berlit, P. (eds) Immunglobuline in der klinischen Neurologie. Steinkopff. https://doi.org/10.1007/978-3-642-93716-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93716-3_6

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-93717-0

  • Online ISBN: 978-3-642-93716-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation